Skip to main content

Advertisement

SpringerLink
Log in

Update on advances and controversy in rectal cancer treatment

  • Review
  • Published:
Techniques in Coloproctology Aims and scope Submit manuscript

Abstract

Changes in the multidisciplinary treatment of rectal cancer have been recently proposed. We performed a comprehensive review of the current data on neoadjuvant and adjuvant treatment of rectal cancer, focussing on chemoradiotherapy treatment and timing of surgery. Six components were proposed as the framework for the treatment of rectal cancer: neoadjuvant therapy and changing patterns in patient selection, long- or short-course radiotherapy, adverse effects of radiotherapy, timing of surgery, non-operative management of rectal cancer and postoperative adjuvant therapy. Lack of a consistent difference in terms of local recurrence has been observed between short-course radiotherapy and long-course chemoradiotherapy. Indications for preoperative radiotherapy have been reconsidered in the last years. An interval of 10–11 weeks seemed to be the optimal timing, with no impact on patient safety. Since assessment criteria of clinical complete response are not well defined, and the basis for non-operative management of rectal cancer is still not clear, further investigations are required. There is controversy about standard treatments for patients with locally advanced rectal cancer that are being analyzed by ongoing studies. Tailored treatments could avoid over-treatment for a large number of patients without any impairment of the oncologic results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Codina-Cazador A, Biondo S (2015) Specialized referral centers for rectal cancer. Cir Esp 93:273–275

    Article  PubMed  Google Scholar 

  2. Ortiz H, Ciga MA, Armendariz P et al (2014) Multicentre propensity score-matched analysis of conventional versus extended abdominoperineal excision for low rectal cancer. Br J Surg 101:874–882

    Article  CAS  PubMed  Google Scholar 

  3. Lujan J, Valero G, Biondo S, Espin E, Parrilla P, Ortiz H (2013) Laparoscopic versus open surgery for rectal cancer: results of a prospective multicentre analysis of 4970 patients. Surg Endosc 27:295–302

    Article  CAS  PubMed  Google Scholar 

  4. Petersen SH, Harling H, Kirkeby LT, Wille-Jørgensen P, Mocellin S (2012) Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev 3:CD004078

    PubMed  Google Scholar 

  5. DeSantis CE, Lin CC, Mariotto AB et al (2014) Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64:252–271

    Article  PubMed  Google Scholar 

  6. Ortiz H, Wibe A, Lujan Ciga MA, Codina A, Biondo S (2013) Impact of a multidisciplinary team training programme on rectal cancer outcomes in Spain. Colorectal Dis 15:544–551

    Article  CAS  PubMed  Google Scholar 

  7. Heald RJ, Husband EM, Ryall RD (1982) The mesorectum in rectal cancer surgery—The clue to pelvic recurrence? Br J Surg 69:613–616

    Article  CAS  PubMed  Google Scholar 

  8. Ortiz H, Wibe A, Ciga MA et al (2014) Multicenter study of outcome in relation to the type of resection in rectal cancer. Dis Colon Rectum 57:811–822

    Article  PubMed  Google Scholar 

  9. Kapiteijn E, Marijnen CA, Nagtegaal ID et al (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638–646

    Article  CAS  PubMed  Google Scholar 

  10. Van Gijn W, Marijnen CAM, Nagtegaal ID et al (2011) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 12:575–582

    Article  PubMed  Google Scholar 

  11. Swedish Rectal Cancer Trial (1997) Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 336:980–987

  12. Cammà C, Giunta M, Fiorica F, Pagliaro L, Craxì A, Cottone M (2000) Preoperative radiotherapy for resectable rectal cancer: A meta-analysis. JAMA 284:1008–1015

    Article  PubMed  Google Scholar 

  13. Figueredo A, Zuraw L, Wong RKS, Agboola O, Rumble RB, Tandan V (2003) The use of preoperative radiotherapy in the management of patients with clinically resectable rectal cancer: a practice guideline. BMC Med 1:1

    Article  PubMed Central  PubMed  Google Scholar 

  14. Glimelius B, Grönberg H, Järhult J, Wallgren A, Cavallin-Ståhl E (2003) A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol 42:476–492

    Article  PubMed  Google Scholar 

  15. Fiorica F, Cartei F, Licata A et al (2010) Can chemotherapy concomitantly delivered with radiotherapy improve survival of patients with resectable rectal cancer? A meta-analysis of literature data. Cancer Treat Rev 36:539–549

    Article  CAS  PubMed  Google Scholar 

  16. Ceelen W, Fierens K, Van Nieuwenhove Y, Pattyn P (2009) Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer: a systematic review and meta-analysis. Int J Cancer 124:2966–2972

    Article  CAS  PubMed  Google Scholar 

  17. Bosset JF, Calais G, Mineur L et al (2005) Enhanced tumourocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results–EORTC 22921. J Clin Oncol 23:5620–5627

    Article  CAS  PubMed  Google Scholar 

  18. Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740

    Article  CAS  PubMed  Google Scholar 

  19. Bosset JF, Collette L, Calais G et al (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114–1123

    Article  CAS  PubMed  Google Scholar 

  20. Gerard JP, Conroy T, Bonnetain F et al (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24:4620–4625

    Article  PubMed  Google Scholar 

  21. Frasson M, Garcia-Granero E, Roda D et al (2011) Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer. Cancer 117:3118–3125

    Article  PubMed  Google Scholar 

  22. Garcia-Aguilar J, Smith DD, Avila K, Bergsland EK, Chu P, Krieg RM (2011) Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg 254:97–102

    Article  PubMed Central  PubMed  Google Scholar 

  23. Schrag D, Weiser MR, Goodman KA, Bergsland EK, Chu P, Krieg RM, Timing of Rectal Cancer Response to Chemoradiation Consortium (2014) Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol 32:513–518

    Article  CAS  PubMed  Google Scholar 

  24. Van Dijk TH, Tamas K, Beukema JC et al (2013) Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer. Ann Oncol 24:1762–1769

    Article  PubMed  Google Scholar 

  25. Bujko K, Nasierowska-Guttmejer A, Wyrwicz L et al (2013) Neoadjuvant treatment for unresectable rectal cancer: an interim analysis of a multicentre randomized study. Radiother Oncol 107:171–177

    Article  PubMed  Google Scholar 

  26. Julien LA, Thorson AG (2010) Current neoadjuvant strategies in rectal cancer. J Surg Oncol 101:321–326

    Article  CAS  PubMed  Google Scholar 

  27. Sebag-Montefiore D, Stephens RJ, Steele R et al (2009) Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 373:811–820

    Article  PubMed Central  PubMed  Google Scholar 

  28. Peeters KCMJ, Marijnen CAM, Nagtegaal ID et al (2007) The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246:693–701

    Article  PubMed  Google Scholar 

  29. Tyc-Szczepaniak D, Wyrwicz L, Kepka L et al (2013) Palliative radiotherapy and chemotherapy instead of surgery in symptomatic rectal cancer with synchronous unresectable metastases: a phase II study. Ann Oncol 24:2829–2834

    Article  CAS  PubMed  Google Scholar 

  30. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M (2006) Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 93:1215–1223

    Article  CAS  PubMed  Google Scholar 

  31. Ngan SY, Burmeister B, Fisher RJ et al (2012) Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 30:3827–3833

    Article  PubMed  Google Scholar 

  32. Pettersson D, Lörinc E, Holm T et al (2015) Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer. Br J Surg 102:972–978

    Article  CAS  PubMed  Google Scholar 

  33. Pollack J, Holm T, Cedermark B et al (2006) Late adverse effects of short-course preoperative radiotherapy in rectal cancer. Br J Surg 93:1519–1525

    Article  CAS  PubMed  Google Scholar 

  34. Pettersson D, Cedermark B, Holm T et al (2010) Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg 97:580–587

    Article  CAS  PubMed  Google Scholar 

  35. Zhou Z-R, Liu S-X, Zhang T-S et al (2014) Short-course preoperative radiotherapy with immediate surgery versus long-course chemoradiation with delayed surgery in the treatment of rectal cancer: a systematic review and meta-analysis. Surg Oncol 23:211–221

    Article  PubMed  Google Scholar 

  36. Bujko K, Bujko M (2011) Point: short-course radiation therapy is preferable in the neoadjuvant treatment of rectal cancer. Semin Radiat Oncol 21:220–227

    Article  PubMed  Google Scholar 

  37. Nilsson PJ, van Etten B, Hospers GAP et al (2013) Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer—the RAPIDO trial. BMC Cancer 13:279

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  38. Dahlberg M, Glimelius B, Graf W, Påhlman L (1998) Preoperative irradiation affects functional results after surgery for rectal cancer: results from a randomized study. Dis Colon Rectum 41:543–549

    Article  CAS  PubMed  Google Scholar 

  39. Frykholm GJ, Glimelius B, Påhlman L (1993) Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects. Dis Colon Rectum 36:564–572

    Article  CAS  PubMed  Google Scholar 

  40. Frykholm GJ, Isacsson U, Nygård K et al (1996) Preoperative radiotherapy in rectal carcinoma. Aspects of acute adverse effects and radiation technique. Int J Radiat Oncol Biol Phys 35:1039–1048

    Article  CAS  PubMed  Google Scholar 

  41. Peeters KCMJ, van de Velde CJH, Leer JWH et al (2005) Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients—a Dutch Colo Rectal Cancer group study. J Clin Oncol 23:6199–6206

    Article  CAS  PubMed  Google Scholar 

  42. Birgisson H, Påhlman L, Gunnarsson U, Glimelius B, Swedish Rectal Cancer Trial Group (2005) Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol 23:8697–8705

    Article  PubMed  Google Scholar 

  43. Holm T, Singnomklao T, Rutqvist LE, Cedermark B (1996) Adjuvant preoperative radiotherapy in patients with rectal carcinoma. Adverse effects during long term follow-up of two randomized trials. Cancer 78:968–976

    Article  CAS  PubMed  Google Scholar 

  44. Minsky BD, Conti JA, Huang Y, Knopf K (1995) Relationship of acute gastrointestinal toxicity and the volume of irradiated small bowel in patients receiving combined modality therapy for rectal cancer. J Clin Oncol 13:1409–1416

    CAS  PubMed  Google Scholar 

  45. Letschert JG, Lebesque JV, de Boer RW, Hart AA, Bartelink H (1990) Dose-volume correlation in radiation-related late small-bowel complications: a clinical study. Radiother Oncol 18:307–320

    Article  CAS  PubMed  Google Scholar 

  46. Syk E, Torkzad MR, Blomqvist L, Ljungqvist O, Glimelius B (2006) Radiological findings do not support lateral residual tumour as a major cause of local recurrence of rectal cancer. Br J Surg 93:113–119

    Article  CAS  PubMed  Google Scholar 

  47. Syk E, Torkzad MR, Blomqvist L, Nilsson PJ, Glimelius B (2008) Local recurrence in rectal cancer: anatomic localization and effect on radiation target. Int J Radiat Oncol Biol Phys 72:658–664

    Article  PubMed  Google Scholar 

  48. Bujko K, Bujko M, Pietrzak L (2006) Clinical target volume for rectal cancer: in regard to Roels et al. (Int J Radiat Oncol Biol Phys 2006;65:1129–142). Int J Radiat Oncol Biol Phys 68:313

    Article  Google Scholar 

  49. Haustermans K, Roels S, Penninckx F (2007) In regards to Bujko et al. (Int J Radiat Oncol Biol Phys 2007;68:313–316). Int J Radiat Oncol Biol Phys 69:639–640

    Article  PubMed  Google Scholar 

  50. Motson RW, Khan JS, Arulampalam TH, Austin RC, Lacey N, Sizer B (2011) Laparoscopic total mesorectal excision following long course chemoradiotherapy for locally advanced rectal cancer. Surg Endosc 25:1753–1760

    Article  PubMed  Google Scholar 

  51. Foster JD, Jones EL, Falk S, Cooper EJ, Francis NK (2013) Timing of surgery after long-course neoadjuvant chemoradiotherapy for rectal cancer: a systematic review of the literature. Dis Colon Rectum 56:921–930

    Article  PubMed  Google Scholar 

  52. Sloothaak DAM, Geijsen DE, van Leersum NJ et al (2013) Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg 100:933–939

    Article  CAS  PubMed  Google Scholar 

  53. Probst CP, Becerra AZ, Aquina CT et al (2015) Extended intervals after neoadjuvant therapy in locally advanced rectal cancer: the key to improved tumour response and potential organ preservation. J Am Coll Surg 221:430–440

    Article  PubMed  Google Scholar 

  54. Maas M, Nelemans PJ, Valentini V et al (2010) Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 11:835–844

    Article  PubMed  Google Scholar 

  55. Biondo S, Ortiz H, Lujan J et al (2010) Quality of mesorectum after laparoscopic resection for rectal cancer—results of an audited teaching programme in Spain. Colorectal Dis 12:24–31

    Article  CAS  PubMed  Google Scholar 

  56. Augestad KM, Lindsetmo R-O, Stulberg J et al (2010) International preoperative rectal cancer management: staging, neoadjuvant treatment, and impact of multidisciplinary teams. World J Surg 34:2689–2700

    Article  PubMed Central  PubMed  Google Scholar 

  57. Habr-Gama A, Perez RO, Nadalin W et al (2004) Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 240:711–717

    PubMed Central  PubMed  Google Scholar 

  58. Habr-Gama A, Perez RO, Proscurshim I et al (2006) Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg 10:1319–1328

    Article  PubMed  Google Scholar 

  59. Smith JD, Ruby JA, Goodman KA et al (2012) Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. Ann Surg 256:965–972

    Article  PubMed  Google Scholar 

  60. Maas M, Beets-Tan RGH, Lambregts DMJ et al (2011) Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 29:4633–4640

    Article  PubMed  Google Scholar 

  61. Dalton RSJ, Velineni R, Osborne ME et al (2012) A single-centre experience of chemoRT for rectal cancer: is there potential for nonoperative management? Colorectal Dis 14:567–571

    Article  CAS  PubMed  Google Scholar 

  62. Hiotis SP, Weber SM, Cohen AM et al (2002) Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg 194:131–135

    Article  PubMed  Google Scholar 

  63. Guillem JG, Chessin DB, Shia J et al (2005) Clinical examination following preoperative chemoradiation for rectal cancer is not a reliable surrogate end point. J Clin Oncol 23:3475–3479

    Article  PubMed  Google Scholar 

  64. Habr-Gama A, Perez RO, Wynn G, Marks J, Kessler H, Gama-Rodrigues J (2010) Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum 53:1692–1698

    Article  PubMed  Google Scholar 

  65. Garcia-Aguilar J, Shi Q, Thomas CR et al (2012) A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial. Ann Surg Oncol 19:384–391

    Article  PubMed  Google Scholar 

  66. Kuo L-J, Chiou J-F, Tai C-J et al (2012) Can we predict pathologic complete response before surgery for locally advanced rectal cancer treated with preoperative chemoradiation therapy? Int J Colorectal Dis 27:613–621

    Article  PubMed  Google Scholar 

  67. Hötker AM, Garcia-Aguilar J, Gollub MJ (2014) Multiparametric MRI of rectal cancer in the assessment of response to therapy: a systematic review. Dis Colon Rectum 57:790–799

    Article  PubMed  Google Scholar 

  68. Habr-Gama A, Gama-Rodrigues J, Perez RO et al (2008) Late assessment of local control by PET in patients with distal rectal cancer managed non-operatively after complete tumour regression following neoadjuvant chemoradiation. Tech Coloproctol 12:74–76

    CAS  PubMed  Google Scholar 

  69. Bujko K, Michalski W, Kepka L et al (2007) Association between pathologic response in metastatic lymph nodes after preoperative chemoradiotherapy and risk of distant metastases in rectal cancer: an analysis of outcomes in a randomized trial. Int J Radiat Oncol Biol Phys 67:369–377

    Article  PubMed  Google Scholar 

  70. Leibold T, Shia J, Ruo L et al (2008) Prognostic implications of the distribution of lymph node metastases in rectal cancer after neoadjuvant chemoradiotherapy. J Clin Oncol 26:2106–2111

    Article  PubMed  Google Scholar 

  71. Mawdsley S, Glynne-Jones R, Grainger J et al (2005) Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3–T4 rectal cancer predict for 3-year disease-free survival? Int J Radiat Oncol Biol Phys 63:745–752

    Article  PubMed  Google Scholar 

  72. Bujko K, Glynne-Jones R, Bujko M (2010) Adjuvant chemotherapy for rectal cancer. Ann Oncol 21:2443

    Article  CAS  PubMed  Google Scholar 

  73. André T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109–3116

    Article  PubMed  Google Scholar 

  74. Wolpin BM, Mayer RJ (2008) Systemic treatment of colorectal cancer. Gastroenterology 134:1296–1310

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  75. Bujko K, Glynne-Jones R, Bujko M (2010) Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. Ann Oncol 21:1743–1750

    Article  CAS  PubMed  Google Scholar 

  76. Bosset JF, Calais G, Mineur L et al (2014) Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 15:184–190

    Article  CAS  PubMed  Google Scholar 

  77. Breugom AJ, van Gijn W, Muller EW et al (2015) Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo) radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol 26:696–701

    Article  CAS  PubMed  Google Scholar 

  78. Sainato A, Cernusco Luna NV, Valentini V et al (2014) No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): long term results of a randomized trial (I-CNR-RT). Radiother Oncol 113:223–229

    Article  PubMed  Google Scholar 

  79. Glynne-Jones R, Counsell N, Quirke P et al (2014) Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol 25:1356–1362

    Article  CAS  PubMed  Google Scholar 

  80. Breugom AJ, Swets M, Bosset JF et al (2015) Adjuvant chemotherapy after preoperative (chemo) radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol 16:200–207

    Article  CAS  PubMed  Google Scholar 

  81. Hong YS, Nam B-H, Kim K-P et al (2014) Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol 15:1245–1253

    Article  CAS  PubMed  Google Scholar 

  82. Rödel C, Graeven U, Fietkau R et al (2015) Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 16:979–989

    Article  PubMed  Google Scholar 

  83. Maas M, Nelemans PJ, Valentini V et al (2015) Adjuvant chemotherapy in rectal cancer: defining subgroups who may benefit after neoadjuvant chemoradiation and resection: A pooled analysis of 3,313 patients. Int J Cancer 137:212–220

    Article  CAS  PubMed  Google Scholar 

  84. Van de Velde CJH, Boelens PG, Borras JM et al (2014) EURECCA colorectal: multidisciplinary management: European consensus conference colon and rectum. Eur J Cancer 50:1.e1–1.e34

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General and Digestive Surgery - Colorectal Unit, University of Barcelona and IDIBELL, Bellvitge University Hospital, C/Feixa Llarga s/n, L’Hospitalet de Llobregat, 08907, Barcelona, Spain

    S. Biondo, D. Fraccalvieri, T. Golda, R. Frago, L. Trenti & E. Kreisler

Authors
  1. S. Biondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Fraccalvieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Golda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Frago
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L. Trenti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Kreisler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Biondo.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

In this article, no patient care was involved.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Biondo, S., Fraccalvieri, D., Golda, T. et al. Update on advances and controversy in rectal cancer treatment. Tech Coloproctol 20, 145–152 (2016). https://doi.org/10.1007/s10151-015-1418-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10151-015-1418-y

Keywords

Search

Navigation